| Characteristics Timing of postoperative adjuvant chemotherapy | P value | ||
|
| ≤2 weeks (n = 75) | 3 - 5 weeks (n = 192) | |
| Gender |
|
| 0.8891 |
| Male | 45 | 118 | |
| Female | 30 | 74 | |
| Age |
|
|
|
| ≤60 years | 50 | 137 | 0.4606 |
| >60 years | 25 | 55 | |
| T stage |
| ||
| T1 | 15 | 34 | 0.3541 |
| T2 | 7 | 31 | |
| T3 | 53 | 127 | |
| N stage |
| ||
| N0 | 42 | 96 | 0.2278 |
| N1 | 16 | 61 | |
| N2 | 17 | 35 | |
| TNM |
| ||
| Stage II | 38 | 90 | 0.5886 |
| Stage III | 37 | 102 | |
| Tumor grade |
| ||
| Well/Moderate differentiation | 46 | 138 | 0.1065 |
| Poor differentiation | 29 | 54 | |
| Specific chemotherapy regimen (may changed during the cycles) | |||
| mFolfox-6 | 37 | 51 | 0.2615 |
| CapeOX | 28 | 130 | |
| Monotherapy | 16 | 18 | |